Tirofiban after intravenous thrombolysis in acute ischemic stroke patients: An updated systematic review and meta-analysis of randomized controlled trials.

Extending the Treatment Window for Intravenous Thrombolysis in Acute Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.

BACKGROUND AND OBJECTIVES Intravenous thrombolysis (IVT) is the standard treatment for acute ischemic stroke within 4.5 hours of onset. However, imaging-based selection may extend the treatment window. This systematic review and meta-analysis evaluated the efficacy and safety of IVT administered beyond 4.5 hours after...

Safety and efficacy of repeated intravenous thrombolysis within 3 months for acute ischemic stroke: a systematic review and individual-patient data meta-analysis

Thrombolysis in the Delayed Treatment Window for Acute Ischemic Stroke: Updated Systematic Review and Meta-Analysis.

BACKGROUND Intravenous thrombolysis is a standard treatment for acute ischemic stroke but has traditionally been limited to 4.5 hours after symptom onset. This time-based restriction may exclude patients with salvageable brain tissue, especially those with wake-up or unknown-onset strokes. Multimodal imaging allows for...

The Safety of Early Intravenous Tirofiban in Acute Ischemic Stroke: A Meta-analysis of Randomized Controlled Trials.

Intravenous Thrombolysis for Minor Ischemic Stroke in Chinese Populations: A Secondary Meta-Analysis of Comparative Cohort Studies.

The effectiveness and safety of intravenous thrombolysis (IVT) in minor ischemic stroke (MIS) remain uncertain in Chinese populations. We performed a secondary meta-analysis of cohort studies identified in a systematic review and meta-analysis, restricting the analysis to studies conducted in Chinese populations with M...

Efficacy and safety of minocycline in acute ischemic stroke: an updated systematic review and meta-analysis with trial sequential analysis of randomized controlled trials

It is suggested that minocycline is biologically credible, but it did not demonstrate a consistent benefit in functional or neurological outcomes after AIS, and minocycline is viewed as a promising adjunct that now needs better targeted, biomarker-informed, reperfusion-aware trials rather than immediate universal use i...